Tuberculosis

Supported pathogenM. tuberculosisMycobacterium tuberculosis

Medicines already documented

Documented evidence

Registered studies whose listed conditions mention “tuberculosis”, “mycobacterium tuberculosis”, “tb”, “latent tb”.

Show all 80

Laboratory measurements against M. tuberculosis recorded in ChEMBL.

Show all 54

Other medicines to investigate

AI prediction · nothing measured

Approved medicines with AI-predicted activity ≥40% against M. tuberculosis that are not already antimicrobials, have no registered study for this condition and have no laboratory record against it. Each shows what it is already used for. They were surfaced computationally for further investigation and are not presented as established treatments for this condition.

M. tuberculosis has 870 repurposing candidates in all. 35 are already listed above, with a registered study for this condition or a laboratory record, so the other 835 are listed here.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Every repurposing candidate for M. tuberculosis, including those with documented evidence →

Registered studies

A registration describes a study; it does not establish a positive result.

When these studies started244 of 249 have a start date · most in 2023 (19)

199420102026

Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)
NCT06674291 · start 2024-11-30
Registered record
Registry ID
NCT06674291
Conditions
Tuberculosis, Multidrug-Resistant
Interventions
No intervention (observational study)
Study type
OBSERVATIONAL
Phase
Not recorded
Registry status
Not yet recruiting
Start
2024-11-30
Completion
2028-12-31
Enrolment
222
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosis, Multidrug-Resistant
InterventionNo intervention (observational study)
PhaseNot recorded
Registry statusNot yet recruiting
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
NCT06649721 · start 2024-11-27
Registered record
Registry ID
NCT06649721
Conditions
Drug-resistant Tuberculosis; Pulmonary Tuberculosis; Rifampin-resistant Tuberculosis
Interventions
bedaquiline; delamanid; linezolid; Levofloxacin; Clofazimine
Study type
INTERVENTIONAL
Phase
Phase 3
Registry status
Active not recruiting
Start
2024-11-27
Completion
2027-06-30
Enrolment
120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDrug-resistant Tuberculosis; Pulmonary Tuberculosis; Rifampin-resistant Tuberculosis
Interventionbedaquiline; delamanid; linezolid; Levofloxacin +1 more
PhasePhase 3
Registry statusActive not recruiting
Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
NCT06281834 · start 2024-11-15
Registered record
Registry ID
NCT06281834
Conditions
Pediatric HIV Infection; Latent Tuberculosis
Interventions
Rifapentine; Dolutegravir
Study type
INTERVENTIONAL
Phase
Phase 1
Registry status
Recruiting
Start
2024-11-15
Completion
2027-06-01
Enrolment
25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPediatric HIV Infection; Latent Tuberculosis
InterventionRifapentine; Dolutegravir
PhasePhase 1
Registry statusRecruiting
Introduction of Dispersible 3HP Formulations for TB Preventive Treatment in Children: a Multi-country Evaluation
NCT06511180 · start 2024-08
Registered record
Registry ID
NCT06511180
Conditions
TB - Tuberculosis; Household Contact; HIV; Children, Only
Interventions
Not recorded
Study type
OBSERVATIONAL
Phase
Not recorded
Registry status
Unknown
Start
2024-08
Completion
2025-06
Enrolment
1,200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTB - Tuberculosis; Household Contact; HIV; Children, Only
InterventionNot recorded
PhaseNot recorded
Registry statusUnknown
BCG Revaccination in Children and Adolescents
NCT05330884 · start 2024-07-15
Registered record
Registry ID
NCT05330884
Conditions
Tuberculosis Infection; Tuberculosis
Interventions
BCG vaccine; Oral Chemoprophylaxis
Study type
INTERVENTIONAL
Phase
Phase 3
Registry status
Suspended
Start
2024-07-15
Completion
2027-12
Enrolment
9,200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosis Infection; Tuberculosis
InterventionBCG vaccine; Oral Chemoprophylaxis
PhasePhase 3
Registry statusSuspended
Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease
NCT05021731 · start 2024-04-20
Registered record
Registry ID
NCT05021731
Conditions
Latent Tuberculosis; Kidney Failure
Interventions
Rifampicin plus Isoniazid; Rifapentine plus Isoniazid; Rifampicin alone
Study type
INTERVENTIONAL
Phase
Phase 4
Registry status
Unknown
Start
2024-04-20
Completion
2025-04-30
Enrolment
225
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLatent Tuberculosis; Kidney Failure
InterventionRifampicin plus Isoniazid; Rifapentine plus Isoniazid; Rifampicin alone
PhasePhase 4
Registry statusUnknown
Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function
NCT03896750 · start 2024-04-17
Registered record
Registry ID
NCT03896750
Conditions
Renal Impairment; Tuberculosis
Interventions
PA-824
Study type
INTERVENTIONAL
Phase
Phase 1
Registry status
Completed
Start
2024-04-17
Completion
2024-10-28
Enrolment
12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRenal Impairment; Tuberculosis
InterventionPA-824
PhasePhase 1
Registry statusCompleted
ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa
NCT06214910 · start 2024-02-20
Registered record
Registry ID
NCT06214910
Conditions
Tuberculosis; HIV I Infection
Interventions
Community-delivered TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP); Clinic-link TPT
Study type
INTERVENTIONAL
Phase
Not applicable
Registry status
Completed
Start
2024-02-20
Completion
2025-08-04
Enrolment
301
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosis; HIV I Infection
InterventionCommunity-delivered TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP); Clinic-link TPT
PhaseNot applicable
Registry statusCompleted
Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis
NCT05630872 · start 2024-02-13
Registered record
Registry ID
NCT05630872
Conditions
HIV-associated Tuberculosis
Interventions
Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC; DTG 50 mg orally QD plus TDF/3TC; 2HPZM; 2HPM
Study type
INTERVENTIONAL
Phase
Phase 2
Registry status
Completed
Start
2024-02-13
Completion
2025-11-12
Enrolment
30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV-associated Tuberculosis
InterventionDolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC; DTG 50 mg orally QD plus TDF/3TC; 2HPZM; 2HPM
PhasePhase 2
Registry statusCompleted
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
NCT05122026 · start 2024-01-17
Registered record
Registry ID
NCT05122026
Conditions
HIV Seropositivity; Pregnancy; Tuberculosis Infection
Interventions
Rifapentine; Isoniazid
Study type
INTERVENTIONAL
Phase
Phase 1 / Phase 2
Registry status
Active not recruiting
Start
2024-01-17
Completion
2025-12-31
Enrolment
252
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Seropositivity; Pregnancy; Tuberculosis Infection
InterventionRifapentine; Isoniazid
PhasePhase 1 / Phase 2
Registry statusActive not recruiting
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
NCT06114628 · start 2024-01-09
Registered record
Registry ID
NCT06114628
Conditions
Pulmonary Tuberculosis
Interventions
Ganfeborole; BTZ-043; Bedaquiline (B); Delamanid (D); Pretomanid (Pa); Moxifloxacin (M); Linezolid (L); Pyrazinamide (Z); Rifampicin (R); Isoniazid (H); Ethambutol (E); Delpazolid (DZD); Quabodepistat (Q)
Study type
INTERVENTIONAL
Phase
Phase 2
Registry status
Recruiting
Start
2024-01-09
Completion
2027-08-11
Enrolment
2,500
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Tuberculosis
InterventionGanfeborole; BTZ-043; Bedaquiline (B); Delamanid (D) +9 more
PhasePhase 2
Registry statusRecruiting
ATORvastatin in Pulmonary TUBerculosis
NCT06199921 · start 2024-01-03
Registered record
Registry ID
NCT06199921
Conditions
Pulmonary Tuberculosis; Tuberculosis; Koch's Disease
Interventions
Atorvastatin 20mg; Atorvastatin 40mg; Atorvastatin 60mg; Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)
Study type
INTERVENTIONAL
Phase
Phase 2
Registry status
Recruiting
Start
2024-01-03
Completion
2026-09-30
Enrolment
440
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Tuberculosis; Tuberculosis; Koch's Disease
InterventionAtorvastatin 20mg; Atorvastatin 40mg; Atorvastatin 60mg; Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)
PhasePhase 2
Registry statusRecruiting
Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial
NCT06727864 · start 2024-01-01
Registered record
Registry ID
NCT06727864
Conditions
Pulmonary Tuberculosis
Interventions
4-month regimen (2HERZ/2HRE); 6-month (2HERZ/4HRE)
Study type
INTERVENTIONAL
Phase
Phase 3
Registry status
Recruiting
Start
2024-01-01
Completion
2028-12-31
Enrolment
270
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Tuberculosis
Intervention4-month regimen (2HERZ/2HRE); 6-month (2HERZ/4HRE)
PhasePhase 3
Registry statusRecruiting
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
NCT06081361 · start 2023-12-22
Registered record
Registry ID
NCT06081361
Conditions
Pulmonary Tuberculosis; Rifampicin-resistant Tuberculosis
Interventions
Bedaquiline; Delamanid; Contezolid; Levofloxacin; Moxifloxacin; Clofazimine; Linezolid; Cycloserine; Prothionamide; Pyrazinamide; Para-Aminosalicylic Acid; Ethambutol
Study type
INTERVENTIONAL
Phase
Phase 3
Registry status
Active not recruiting
Start
2023-12-22
Completion
2026-12-31
Enrolment
186
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Tuberculosis; Rifampicin-resistant Tuberculosis
InterventionBedaquiline; Delamanid; Contezolid; Levofloxacin +8 more
PhasePhase 3
Registry statusActive not recruiting
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis
NCT05556746 · start 2023-11-24
Registered record
Registry ID
NCT05556746
Conditions
Tuberculosis, Pulmonary; HIV
Interventions
Bedaquiline (BDQ); Clofazimine (CFZ); Pyrazinamide (PZA); Delamanid (DLM); Rifampicin (RIF); Isoniazid (INH); Ethambutol (EMB); Pyrazinamide (PZA)
Study type
INTERVENTIONAL
Phase
Phase 2
Registry status
Active not recruiting
Start
2023-11-24
Completion
2027-01
Enrolment
94
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosis, Pulmonary; HIV
InterventionBedaquiline (BDQ); Clofazimine (CFZ); Pyrazinamide (PZA); Delamanid (DLM) +4 more
PhasePhase 2
Registry statusActive not recruiting